We are live on ! Find out more
OVID icon

Ovid Therapeutics
OVID

88 hedge funds and large institutions have $146M invested in Ovid Therapeutics in 2021 Q1 according to their latest regulatory filings, with 22 funds opening new positions, 26 increasing their positions, 22 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

126% more capital invested

Capital invested by funds: $64.5M → $146M (+$81.2M)

38% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 16

18% more repeat investments, than reductions

Existing positions increased: 26 | Existing positions reduced: 22

11.63% more ownership

Funds ownership: 43.51% → 55.14% (+12%)

6% more funds holding

Funds holding: 83 → 88 (+5)

69% less call options, than puts

Call options by funds: $1.25M | Put options by funds: $4.02M

Holders
88
Holders Change
+5
Holders Change %
+6.02%
% of All Funds
1.54%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
22
Increased
26
Reduced
22
Closed
16
Calls
$1.25M
Puts
$4.02M
Net Calls
-$2.77M
Net Calls Change
-$2.27M

Top Buyers

Rank Fund Capital Flow
1
EC
EcoR1 Capital
California
+$20.2M
2
SCM
Stonepine Capital Management
Oregon
+$8.25M
3
BI
BVF Inc
California
+$6.3M
4
IC
Ikarian Capital
Texas
+$3.74M
5
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$2.03M

Top Sellers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
-$3.35M
2
VC
Vivo Capital
California
-$2.89M
3
BBA
Baker Bros. Advisors
New York
-$2.21M
4
CA
CHI Advisors
New York
-$1.93M
5
Renaissance Technologies
Renaissance Technologies
New York
-$1.64M
Name Holding Trade Value Shares
Change 		Change in
Stake
Bank of New York Mellon
26
Bank of New York Mellon
New York
$607K +$52.4K +15,767 +12%
BFM
27
Boothbay Fund Management
New York
$530K +$438K +131,834 New
AQR Capital Management
28
AQR Capital Management
Connecticut
$491K +$304K +91,672 +302%
RG
29
Redmile Group
California
$490K – – –
Charles Schwab
30
Charles Schwab
California
$478K +$36.2K +10,896 +10%
DA
31
DCF Advisers
Connecticut
$438K +$362K +109,001 New
First Trust Advisors
32
First Trust Advisors
Illinois
$429K +$28.5K +8,573 +9%
Russell Investments Group
33
Russell Investments Group
United Kingdom
$419K +$346K +104,283 New
Simplex Trading
34
Simplex Trading
Illinois
$369K +$182K +54,868 +148%
California Public Employees Retirement System
35
California Public Employees Retirement System
California
$351K -$27.3K -8,224 -9%
Citadel Advisors
36
Citadel Advisors
Florida
$329K +$13.2K +3,963 +5%
Morgan Stanley
37
Morgan Stanley
New York
$314K -$240K -72,179 -48%
GCP
38
GSA Capital Partners
United Kingdom
$305K -$385K -115,945 -60%
Royal Bank of Canada
39
Royal Bank of Canada
Ontario, Canada
$301K -$24.8K -7,479 -9%
California State Teachers Retirement System (CalSTRS)
40
California State Teachers Retirement System (CalSTRS)
California
$289K – – –
FC
41
Fairpointe Capital
Illinois
$288K -$166K -50,000 -41%
SSA
42
Schonfeld Strategic Advisors
New York
$257K +$213K +64,000 New
AllianceBernstein
43
AllianceBernstein
Tennessee
$226K – – –
RhumbLine Advisers
44
RhumbLine Advisers
Massachusetts
$197K -$2.26K -680 -1%
CSS
45
Cubist Systematic Strategies
Connecticut
$197K +$162K +48,891 New
HS
46
HighVista Strategies
Massachusetts
$164K – – –
Barclays
47
Barclays
United Kingdom
$161K +$82.1K +24,718 +161%
Jane Street
48
Jane Street
New York
$161K +$133K +40,111 New
New York State Common Retirement Fund
49
New York State Common Retirement Fund
New York
$157K – – –
T. Rowe Price Associates
50
T. Rowe Price Associates
Maryland
$148K +$122K +36,748 New
1
2
3 4 5

OVID Hedge Fund Activity: Q1 2021 in Review

88 of the 5,696 institutional investors tracked by Wall St. Rank reported a position in Ovid Therapeutics (OVID) for Q1 2021, worth a combined $146M — up 126% from $64.5M a quarter earlier.

Buyers outnumbered sellers: 22 funds opened new OVID positions and 16 closed out — a net gain of 6 holders — while 26 added to existing stakes and 22 trimmed.

The largest buyer was EcoR1 Capital, opening a new position worth an estimated $20.2M. The largest seller was UBS Group, cutting an estimated $3.35M.

  • 88 institutional investors held Ovid Therapeutics (OVID) as of Q1 2021, up from 83 in Q4 2020.
  • Funds reported $146M of Ovid Therapeutics stock for Q1 2021, up 126% quarter-over-quarter.
  • 22 funds opened new Ovid Therapeutics positions in Q1 2021 and 16 closed out, a net change of +6 holders.
  • The largest Ovid Therapeutics buyer in Q1 2021 was EcoR1 Capital, an estimated $20.2M added.
  • The largest Ovid Therapeutics seller in Q1 2021 was UBS Group, an estimated $3.35M sold.

Based on aggregated 13F filings for Q1 2021.